CryoLife, Inc. (NYSE:CRY) – Analysts at First Analysis decreased their Q3 2017 earnings per share estimates for CryoLife in a report issued on Monday. First Analysis analyst now forecasts that the medical equipment provider will earn $0.06 per share for the quarter, down from their previous forecast of $0.11. First Analysis also issued estimates for CryoLife’s Q4 2017 earnings at $0.10 EPS and Q2 2018 earnings at $0.10 EPS.
CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter last year, the company posted $0.13 EPS. The company’s revenue was up 1.5% compared to the same quarter last year.
Other analysts have also issued research reports about the stock. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday. Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research note on Friday, April 28th. Finally, Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Thursday, June 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.00.
CryoLife (NYSE:CRY) opened at 18.65 on Tuesday. The company’s 50 day moving average is $19.35 and its 200-day moving average is $17.95. The stock has a market cap of $623.77 million, a PE ratio of 56.52 and a beta of 0.99. CryoLife has a 1-year low of $13.88 and a 1-year high of $20.30.
In related news, VP Amy Horton sold 9,577 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 6.00% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in CRY. Trexquant Investment LP purchased a new stake in CryoLife during the second quarter valued at approximately $291,000. Essex Investment Management Co. LLC raised its stake in CryoLife by 21.9% in the second quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the medical equipment provider’s stock valued at $2,351,000 after buying an additional 21,206 shares in the last quarter. Texas Permanent School Fund raised its stake in CryoLife by 1.7% in the second quarter. Texas Permanent School Fund now owns 19,913 shares of the medical equipment provider’s stock valued at $397,000 after buying an additional 333 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in CryoLife by 3.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 230 shares in the last quarter. Finally, Thomson Horstmann & Bryant Inc. purchased a new stake in CryoLife during the second quarter valued at approximately $1,873,000. Institutional investors own 68.15% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.